Future Directions of BTK Inhibitors in Leukemia and Lymphoma

EP: 1.Recent Trends and Innovations in the Management of CLL

EP: 2.CLL Treatment Landscape: Overview of BTK Inhibitors

EP: 3.Evaluating Value of BTK Inhibitors in CLL Treatment

EP: 4.Factors Influencing Choice of Second-Generation BTKi Monotherapy

EP: 5.Empowering Patients: Key Considerations for BTK Inhibitor Adherence

EP: 6.Optimizing Therapy Sequencing in CLL

EP: 7.Leveraging MAICs for Decision-Making in CLL BTK Inhibitor Selection

EP: 8.Decision-Making in CLL: The Role of Real-World Evidence

EP: 9.Combination Regimens with BTK Inhibitors: New Frontiers in CLL Treatment

EP: 10.Financial Challenges of BTK Inhibitor Therapy in CLL: Impact on Access and Utilization

EP: 11.Navigating Access Challenges in CLL Treatment: Strategies for Overcoming Barriers 

EP: 12.The Inflation Reduction Act: Implications for Patient Access in CL

EP: 13.Patient Access Advocacy for BTK Inhibitors

Now Viewing

EP: 14.Future Directions of BTK Inhibitors in Leukemia and Lymphoma

Video content above is prompted by the following:

• Let’s discuss anticipated (or just presented) data from ASCO 2024 on the treatment of CLL. What data or insights are you most looking forward to coming out of ASCO 2024?
• How might emerging biomarkers influence the development and use of BTK inhibitors in CLL?